Thuja Capital adds Dr. Staf Van Reet to its scientific advisory board

Date: 15/12/2010

Utrecht, The Netherlands – Thuja Capital today announced that Dr. Staf Van Reet has joined its Scientific Advisory Board.

Dr. Van Reet has a long track record, among others as the Managing Director of Janssen Pharmaceutica N.V. and President of the Janssen Research Foundation, the worldwide research and development activities of the Janssen Group of companies. Additionally, Staf has solid experience in venture capital, having been responsible for corporate venturing in Europe as a Vice President of the Johnson & Johnson Development Corporation. Staf also gained extensive experience in the biotech sector as co-founder of Movetis and Chairman of its Board of Directors until the acquisition of the company by Shire.

Currently, he is still active in various areas of the life sciences, among others as the founder and CEO of Viziphar Biosciences, as Chairman of the Board of Okapi Sciences and a Board member of Thrombogenics and of VIB, the Flemish Institute of Biotechnology.

Harrold van Barlingen, Managing Partner of Thuja Capital Management, comments: “Staf is a great addition to our Scientific Advisory Board. Given his track record and highly relevant experience and international network he can further help us to make our funds successful.”